# Nicolas Girard
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/nicolas-girard/
## Facts
| Field | Value |
| --- | --- |
| Citations | 33,375 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 82 |
| i10-index | 279 |
| Last Known Institution | Institut Curie |
| OpenAlex ID | https://openalex.org/A5090329560 |
| ORCID iD | 0000-0001-9909-2299 |
| Works | 904 |
## Researcher papers
Showing 12 of 18.
- [New driver mutations in non-small-cell lung cancer](https://scholariq.org/papers/new-driver-mutations-in-non-small-cell-lung-cancer/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes](https://scholariq.org/papers/the-2015-world-health-organization-classification-of-tumors-of-the-thymus/)
- [Deep learning-based classification of mesothelioma improves prediction of patient outcome](https://scholariq.org/papers/deep-learning-based-classification-of-mesothelioma-improves-prediction-of/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions](https://scholariq.org/papers/amivantamab-plus-chemotherapy-in-nsclc-with-i-egfr-i-exon-20-insertions/)
- [PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee](https://scholariq.org/papers/pd-l1-testing-for-lung-cancer-in-2019-perspective-from-the-iaslc-pathology/)
- [Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study](https://scholariq.org/papers/treatment-characteristics-and-real-world-progression-free-survival-in-patients/)
- [Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids](https://scholariq.org/papers/integrative-and-comparative-genomic-analyses-identify-clinically-relevant/)
- [Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002](https://scholariq.org/papers/noninvasive-diagnosis-of-actionable-mutations-by-deep-sequencing-of-circulating/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
## Researcher university
- [Institut Curie](https://scholariq.org/institutions/institut-curie/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.